Timothy Pluard, MD, discusses recent data from an age-based subgroup analysis of RIGHT Choice, which compares the efficacy of combination ribociclib/ET versus chemotherapy in the first-line treatment of HR+/HER2- advanced breast cancer.
Experts on HR+/HER2- breast cancer review recent real-world data on CDK4/6 inhibitors and share excitement about first-line trials that have not yet read out.
LONDON (dpa-AFX) - AstraZeneca (AZN) said results from the SERENA-2 Phase II trial showed that its next-generation oral selective estrogen receptor degrader (ngSERD) camizestrant demonstrated a
LONDON (dpa-AFX) - British drug major AstraZeneca plc (AZN.L) said that results from SERENA-2 Phase II trial showed that camizestrant provided a significant improvement in progression-free survival